VEGF-A/ VEGFR2 Y949を標的とする 信号媒介による血管透過性は 低毒性肺高血圧を緩和する
Weibin Zhou1,2,3, Keli Liu2, Lei Zeng2
1Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China (W.Z., J.H., M.W., D.W., J.W., Y.C.).
Circulation
|November 17, 2022
まとめ
肺高血圧は,VEGF-A/ VEGFR2 Y949シグナル伝達によって引き起こされる過度の血管漏れを伴う. この特定の経路をターゲットにすると,すべてのVEGFR2シグナリングをブロックするとは異なり,病気を緩和します.
科学分野:
- 心血管研究
- 肺医学
- 分子生物学
背景:
- 肺高血圧 (PH) は,血管内皮成長因子A (VEGF-A) およびその受容体VEGFR2の増加と関連しています.
- VEGF-Aシグナル伝達のPH病原性における正確な役割は不明である.
研究 の 目的:
- PHにおけるVEGF-A/VEGFR2シグナル伝達とVEGFR2 Y949依存性血管漏れの役割を調査する.
- 低酸素PHに伴うメカニズム的経路を解明する.
主な方法:
- PH患者と低酸素にさらされたマウスの肺サンプルを検査した.
- VEGFR2 Y949フェニララニンノックインと内皮特異のVegfr2デレーションを用いた変異性マウス.
- 右心室の収縮圧,高縮,肺血管病気が評価されました.
主要な成果:
- 過剰に活性化されたVEGF-A/VEGFR2 Y949シグナリングによって,PHは過剰な肺血管漏れを引き起こします.
- VEGFR2 Y949のシグナル伝達には Yes1,c-Src,VE-カデリンリン酸化が関与し,血管の透過性を引き起こす.
- VEGFR2 Y949の信号を遮断するとPHの症状は改善され,VEGFR2の完全な消去はPHを悪化させた.
結論:
- VEGF-A/VEGFR2 Y949に依存する血管透過性は,PHの病原性における重要な要因である.
- VEGF-A/ VEGFR2 Y949軸は,PHの潜在的な治療目標を表しています.
関連する概念動画
Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
Pulmonary Hypertension: Classification and Pathogenesis
265
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
265
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
219
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
219
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
305
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
305


